Skip to content

Trial Summary

An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-573 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Metastatic Solid Tumors

Acronym:

TAK-573-1001

ACTRN/NCT /ethics:

NCT04157517

Scientific title:

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Metastatic Solid Tumors

Sponsor / Cooperative group:

Takeda

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I; Phase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2019-12-12
Anticipated End Date2023-08-02

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Emailstella.papacharissiou@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusNot Yet Recruiting